TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
TRxADE Health, Inc. has changed its name to Scienture Holdings, Inc. and its ticker symbol to "SCNX", effective September 23, 2024. The company will continue to trade on the Nasdaq Stock Market. Scienture Holdings, Inc., through its wholly owned subsidiaries Scienture and Integra Pharma Solutions, , is a comprehensive pharmaceutical product company focused on providing novel specialty products to meet unmet market needs.
The company's products are in development across various therapeutic areas and indications, catering to different market segments and channels. The executive team and board of directors consist of experienced industry veterans, including Suren Ajjarapu as CEO and Chairman, Prashant Patel as President, Interim CFO and COO, and other accomplished members.
TRxADE Health, Inc. ha cambiato il suo nome in Scienture Holdings, Inc. e il suo simbolo di borsa in "SCNX", a partire dal 23 settembre 2024. L'azienda continuerà a essere quotata sul Nasdaq Stock Market. Scienture Holdings, Inc., attraverso le sue controllate interamente possedute Scienture e Integra Pharma Solutions, è un azienda farmaceutica completa focalizzata sulla fornitura di nuovi prodotti specializzati per soddisfare le esigenze di mercato insoddisfatte.
I prodotti dell'azienda sono in fase di sviluppo in diversi ambiti terapeutici e indicazioni, rivolgendo attenzione a vari segmenti di mercato e canali. Il team esecutivo e il consiglio di amministrazione sono composti da esperti del settore, tra cui Suren Ajjarapu come CEO e Presidente, Prashant Patel come Presidente, CFO e COO ad interim, e altri membri di successo.
TRxADE Health, Inc. ha cambiado su nombre a Scienture Holdings, Inc. y su símbolo de cotización a "SCNX", efectivo el 23 de septiembre de 2024. La compañía continuará cotizando en el Nasdaq Stock Market. Scienture Holdings, Inc., a través de sus subsidiarias de propiedad total Scienture e Integra Pharma Solutions, es una empresa farmacéutica integral que se enfoca en proporcionar productos especializados novedosos para satisfacer las necesidades insatisfechas del mercado.
Los productos de la empresa están en desarrollo en diversas áreas terapéuticas e indicaciones, atendiendo a diferentes segmentos de mercado y canales. El equipo ejecutivo y la junta directiva están compuestos por veteranos experimentados de la industria, incluyendo a Suren Ajjarapu como CEO y Presidente, Prashant Patel como Presidente, CFO interino y COO, y otros miembros destacados.
TRxADE Health, Inc.는 이름을 Scienture Holdings, Inc.로 변경했습니다. 그리고 티커 기호는 "SCNX"로 변경되었습니다. 이는 2024년 9월 23일부터 유효합니다. 회사는 Nasdaq 주식 시장에서 계속 거래될 것입니다. Scienture Holdings, Inc.는 완전 자회사인 Scienture와 Integra Pharma Solutions를 통해 종합 제약 제품 회사로, 충족되지 않은 시장 요구를 충족하기 위한 혁신적인 전문 제품을 제공하는 데 초점을 맞추고 있습니다.
회사의 제품은 다양한 치료 분야와 적응증에 걸쳐 개발 중에 있으며, 시장의 다양한 세그먼트 및 채널을 대상으로 하고 있습니다. 경영진과 이사회는 Suren Ajjarapu(CEO 겸 의장), Prashant Patel(사장, 임시 CFO 및 COO) 등 업계 경험이 풍부한 전문가들로 구성되어 있습니다.
TRxADE Health, Inc. a changé son nom en Scienture Holdings, Inc. et son symbole boursier en "SCNX", effectif à partir du 23 septembre 2024. L'entreprise continuera à être cotée sur le Nasdaq Stock Market. Scienture Holdings, Inc., à travers ses filiales en propriété exclusive Scienture et Integra Pharma Solutions, est une entreprise pharmaceutique complète axée sur la fourniture de nouveaux produits spécialisés pour répondre aux besoins du marché non satisfaits.
Les produits de l'entreprise sont en développement dans divers domaines thérapeutiques et indications, s'adressant à différents segments et canaux de marché. L'équipe de direction et le conseil d'administration sont composés de vétérans expérimentés de l'industrie, y compris Suren Ajjarapu en tant que PDG et Président, Prashant Patel en tant que Président, CFO par intérim et COO, ainsi que d'autres membres accomplis.
TRxADE Health, Inc. hat seinen Namen in Scienture Holdings, Inc. geändert und sein Börsenkürzel in "SCNX", gültig ab dem 23. September 2024. Das Unternehmen wird weiterhin an der Nasdaq Stock Market gehandelt. Scienture Holdings, Inc. ist durch seine vollständig im Besitz befindlichen Tochtergesellschaften Scienture und Integra Pharma Solutions eine umfassende Pharmafirma, die sich darauf konzentriert, neue Spezialprodukte anzubieten, um unerfüllte Marktbedürfnisse zu decken.
Die Produkte des Unternehmens befinden sich in verschiedenen therapeutischen Bereichen und Indikationen in der Entwicklung, wobei verschiedene Marktsegmente und -kanäle angesprochen werden. Das Führungsteam und der Vorstand setzen sich aus erfahrenen Branchenveteranen zusammen, darunter Suren Ajjarapu als CEO und Chairman, Prashant Patel als Präsident, Interim CFO und COO sowie anderen erfolgreichen Mitgliedern.
- Name change to Scienture Holdings, Inc. may reflect a new strategic direction
- Continued listing on Nasdaq Stock Market maintains visibility and liquidity for investors
- Focus on novel specialty products to address unmet market needs could lead to new revenue streams
- Experienced executive team and board with industry expertise
- None.
Insights
The name change from TRxADE Health to Scienture Holdings and ticker symbol change from MEDS to SCNX represent a significant rebranding effort, potentially signaling a shift in the company's strategic direction. This move aligns the parent company's identity more closely with its Scienture subsidiary, suggesting a greater focus on pharmaceutical product development and specialty medications.
While name changes alone don't typically impact financial performance directly, they can influence investor perception and market positioning. The emphasis on being a "comprehensive pharmaceutical product company" may attract investors interested in the specialty pharma sector. However, without specific financial data or product pipeline information, it's challenging to assess the immediate impact on the company's valuation or future prospects.
Investors should closely monitor upcoming announcements for details on Scienture's product portfolio, development pipeline and any changes in business strategy that may accompany this rebranding. The retention of key leadership, including CEO Suren Ajjarapu and the addition of industry veterans to the board, provides continuity and potentially valuable expertise in navigating the pharmaceutical market.
TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively, and that the business will continue as a Nasdaq-listed company.
TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the “Company”) (Nasdaq: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to “Scienture Holdings, Inc.” Effective as of September 23, 2024, the Company’s stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol ”SCNX”.
Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions, LLC (“IPS”), is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products are in development across therapeutic areas and indications, and cater to different market segments and channels.
Our executive team and board of directors, listed below, consist of accomplished industry veterans, bringing many years of experience and leadership.
Suren Ajjarapu – CEO of the Company and Chairman of the Board of Directors (the “Board”)
Prashant Patel – President, Interim CFO and COO of the Company and Member of the Board
Shankar Hariharan, Ph.D. – CEO of Scienture and Member of the Board Narasimhan Mani, Ph.D., MBA – President of Scienture and Member of the Board
Donald Fell – Member of the Board
Mayur Doshi – Member of the Board
Subbarao Jayanthi – Member of the Board
About Scienture, LLC
Scienture, LLC is a NY based pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Scienture is a fully fitted company with strategic capabilities across R&D, Manufacturing, Sales and Marketing and Commercial Operations. For more information, visit Scienture’s website at www.scienture.com/scienture-llc/.
About Integra Pharma Solutions, LLC
Integra Pharma Solutions, LLC is the pharmaceutical supplier of choice for healthcare organizations of all sizes. Our expertise in the distribution of products extends all healthcare markets including Government Organizations, Hospitals, Clinics, and Independent Pharmacies nationwide. IPS holds pharmaceuticals distributor licenses in 39 states and supplies pharmaceuticals, diabetic supplies, veterinary, PPE products and more. It offers efficient solutions to manufacturers and distributors to further lower cost and increase pharmaceutical access. For more information, visit IPS’ website at www.rxintegra.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contacts:
Scienture Holdings, Inc.
Scienture Holdings, Inc.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Rxintegra.com
Scienture, LLC
Scienture, LLC
20 Austin Boulevard
Commack, New York 11725
Phone: (631) 670-6039
Email: IR@Scienture.com
FAQ
What is the new name and ticker symbol for TRxADE Health, Inc.?
When did the name and ticker symbol change for SCNX take effect?
What is the main focus of Scienture Holdings, Inc. (SCNX)?
Who are the key executives of Scienture Holdings, Inc. (SCNX)?
